Hiroshi Imoto

Summary

Affiliation: Pharmaceutical Research Division
Country: Japan

Publications

  1. ncbi request reprint Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives
    Hiroshi Imoto
    Takeda Chemical Industries, Ltd, Pharmaceutical Research Division, Osaka, Japan
    Chem Pharm Bull (Tokyo) 50:1349-57. 2002
  2. ncbi request reprint Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents
    Hiroshi Imoto
    Takeda Chemical Industries, Ltd, Pharmaceutical Research Division, Osaka, Japan
    Chem Pharm Bull (Tokyo) 51:138-51. 2003
  3. ncbi request reprint Studies on non-thiazolidinedione antidiabetic agents. 3. Preparation and biological activity of the metabolites of TAK-559
    Hiroshi Imoto
    Pharmaceutical Research Division, Takeda Chemical Industries Ltd, 2 17 85 Juso Honmachi, Yodogawa ku, Osaka 532 8686, Japan
    Chem Pharm Bull (Tokyo) 52:120-4. 2004
  4. doi request reprint Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists
    Kentaro Rikimaru
    Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 20:3332-58. 2012
  5. ncbi request reprint A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes
    Junichi Sakamoto
    Pharmaceutical Discovery Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, Osaka, Japan
    Eur J Pharmacol 495:17-26. 2004
  6. doi request reprint A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides
    Kentaro Rikimaru
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 20:714-33. 2012
  7. ncbi request reprint Orally active CCR5 antagonists as anti-HIV-1 agents 2: synthesis and biological activities of anilide derivatives containing a pyridine N-oxide moiety
    Masaki Seto
    Medicinal Chemistry Research Laboratries, Pharmaceutical Research Division, Takeda Chemical Industries Ltd Osaka, Japan
    Chem Pharm Bull (Tokyo) 52:818-29. 2004

Collaborators

  • Yu Momose
  • Junichi Sakamoto
  • Masanori Baba
  • Tsuyoshi Maekawa
  • Masaki Seto
  • Kentaro Rikimaru
  • Miyuki Funami
  • Yoshiaki Horiguchi
  • Naoto Arimura
  • Takeshi Wakabayashi
  • Gyorgy P Snell
  • Chisako Nomura
  • Kazutoshi Kawakami
  • Katsuhito Murase
  • Nozomi Katayama
  • Kenneth A Bragstad
  • Hidenori Abe
  • Douglas R Dougan
  • Clifford D Mol
  • Hiroko Tsuge
  • Mitsuharu Matsumoto
  • Toshimasa Tanaka
  • Takanori Matsuo
  • Bi Ching Sang
  • Jinichi Yonemori
  • Hideki Hirose
  • Taisuke Tawaraishi
  • Osamu Ujikawa

Detail Information

Publications7

  1. ncbi request reprint Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives
    Hiroshi Imoto
    Takeda Chemical Industries, Ltd, Pharmaceutical Research Division, Osaka, Japan
    Chem Pharm Bull (Tokyo) 50:1349-57. 2002
    ..01) and plasma triglycelide levels (43%, p<0.01) even at a dosage of 0.001% in diet. Pharmacokinetic analyses of 25 are also reported...
  2. ncbi request reprint Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents
    Hiroshi Imoto
    Takeda Chemical Industries, Ltd, Pharmaceutical Research Division, Osaka, Japan
    Chem Pharm Bull (Tokyo) 51:138-51. 2003
    ..Compound (27) (TAK-559) showed favorable pharmacokinetic properties with good absorption and duration, and was considered as an attractive candidate for further evaluation...
  3. ncbi request reprint Studies on non-thiazolidinedione antidiabetic agents. 3. Preparation and biological activity of the metabolites of TAK-559
    Hiroshi Imoto
    Pharmaceutical Research Division, Takeda Chemical Industries Ltd, 2 17 85 Juso Honmachi, Yodogawa ku, Osaka 532 8686, Japan
    Chem Pharm Bull (Tokyo) 52:120-4. 2004
    ..TAK-559 (1) showed potent in vivo plasma glucose and triglyceride lowering activities in Wistar fatty rats after intraperitoneal administration, while its metabolites (2-5) showed comparatively weak activities...
  4. doi request reprint Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists
    Kentaro Rikimaru
    Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 20:3332-58. 2012
    ..Structure-activity relationship study as well as detailed analysis of the binding mode of 8f to the PPARγ-LBD revealed the essential structural features of this series of ligands...
  5. ncbi request reprint A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes
    Junichi Sakamoto
    Pharmaceutical Discovery Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, Osaka, Japan
    Eur J Pharmacol 495:17-26. 2004
    ..Taken together, we conclude that TAK-559 is a dual agonist for hPPARgamma1 and hPPARalpha with nearly equal EC50 values, a partial agonist for hPPARgamma1, and has a rather slight agonist activity for hPPARdelta...
  6. doi request reprint A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides
    Kentaro Rikimaru
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 20:714-33. 2012
    ..Further, we have described the difference in binding mode of the carboxylic-acid-based agonist 1 and acylsulfonamide 3d...
  7. ncbi request reprint Orally active CCR5 antagonists as anti-HIV-1 agents 2: synthesis and biological activities of anilide derivatives containing a pyridine N-oxide moiety
    Masaki Seto
    Medicinal Chemistry Research Laboratries, Pharmaceutical Research Division, Takeda Chemical Industries Ltd Osaka, Japan
    Chem Pharm Bull (Tokyo) 52:818-29. 2004
    ..In particular, compound (S)-5s showed the most potent CCR5 antagonistic activity (IC(50)=7.2 nM) and inhibitory effect (IC(50)=5.4 nM) in the fusion assay, together with good pharmacokinetic properties in rats...